Related Experiment Video
Updated: Jun 11, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Prognostic value of excision repair cross-complementing gene 1 expression for cisplatin-based chemotherapy in
Metin Ozkan1, Ismail Hakki Akbudak, Kemal Deniz
1Department of Medical Oncology, Medical Faculty, Erciyes University, Kayseri, Turkey. metino@erciyes.edu.tr
Background:
Association of excision repair cross-complementing gene 1 (ERCC1) expression and treatment response and survival was evaluated in advanced stages of gastric cancer patients who were given different platinum-based chemotherapy.
Patients And Methods:
Forty-one patients with advanced gastric cancer were enrolled into the study from January 2000 to December 2009. ERCC1 expression was evaluated by immunohistochemistry (IHC).
Results:
Thirteen of the 41 patients (31%) were shown to have ERCC1 positive lesions. Although the clinical benefit from platin based chemotherapy was the same for ERCC1 positive and negative patients, survival times were statistically significantly better in ERCC1 negative gastric cancer patients.
Conclusion:
We suggest that IHC studies for ERCC1 may be useful in prediction of the clinical outcome of advanced gastric cancer patients treated with platin-based chemotherapy.
